# Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

> **NCT04066790** · PHASE2 · TERMINATED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** nab-Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** EC chemotherapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT04066790
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-09
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** We terminated this trial and initiated a new one including pertuzumab.
- **Last updated:** 2020-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04066790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04066790, "Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04066790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*